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Abstract
Improved biomarkers of acute nephrotoxicity are coveted by the drug development industry, regulatory agencies, and
clinicians. In an effort to identify such biomarkers, urinary peptide profiles of rats treated with two different nephrotoxins
were investigated. 493 marker candidates were defined that showed a significant response to cis-platin comparing a cis-
platin treated cohort to controls. Next, urine samples from rats that received three consecutive daily doses of 150 or
300 mg/kg gentamicin were examined. 557 potential biomarkers were initially identified; 108 of these gentamicin-
response markers showed a clear temporal response to treatment. 39 of the cisplatin-response markers also displayed a
clear response to gentamicin. Of the combined 147 peptides, 101 were similarly regulated by gentamicin or cis-platin and
54 could be identified by tandem mass spectrometry. Most were collagen type I and type III fragments up-regulated in
response to gentamicin treatment. Based on these peptides, classification models were generated and validated in a
longitudinal study. In agreement with histopathology, the observed changes in classification scores were transient,
initiated after the first dose, and generally persistent over a period of 10–20 days before returning to control levels. The
data support the hypothesis that gentamicin-induced renal toxicity up-regulates protease activity, resulting in an increase
in several specific urinary collagen fragments. Urinary proteomic biomarkers identified here, especially those common to
both nephrotoxins, may serve as a valuable tool to investigate potential new drug candidates for the risk of
nephrotoxicity.
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Introduction
The drug development industry, government regulatory
agencies, and healthcare professionals are all major stakeholders
in the development of biomarkers of drug-induced injury. The
advancement of organ-specific biomarkers of drug-induced injury
promises each stakeholder improved efficiency and effectiveness in
the drug development process that ultimately results in safe and
efficacious products coming to the market. The United States
Food and Drug Administration (U. S. FDA) has gone as far as
describing an official biomarker qualification process [1] to hasten
adoption of candidate biomarkers. Kidney injury biomarkers were
the logical test case for the biomarker qualification process.
Classical, functional biomarkers of kidney injury (blood urea
nitrogen, serum creatinine), while accessible (serum, plasma), are
not sensitive or specific to etiology or location of injury, leaving
considerable room for biomarker improvement. Individual
biomarkers have been evaluated and qualified by the U. S. FDA
based on validated immune-based assays and data packages put
together by industrial consortia [2]. Ongoing evaluation of these
biomarkers suggests that specific insults may illicit different
biomarker responses and that building biomarker profiles might
be the ultimate tool for identifying injury [3–5]. As a consequence,
there is a specific need for additional biomarkers that enable the
generation of such specific biomarker profiles. Ideally, the
biomarkers should be easily accessible in a non-invasive way,
and should be applicable in animal models, as well as in man.
‘‘Omic’’ technologies (genomics, metabolomics, proteomics,
etc.) hold the promise to fulfil this need and enable identification
of multiple biomarkers that reflect specific types of injury in the
kidney. Several proteomics approaches have been described in this
context [6–9]. CE-MS methodology was validated as an analytical
tool for the measurement of peptides in rat urine and subsequently
used to profile the urinary low-molecular proteome of the rat [10].
In an earlier publication [11], CE-MS was used as a biomarker
discovery tool for nephrotoxicity in rats treated with cis-platin. In
the study reported here we aimed to identify common and
disparate biomarkers of cis-platin- and gentamicin-induced
nephrotoxicity by applying CE-MS proteomics in rat urine. The
aim of the study was to detect multiple biomarkers that can be
efficiently analysed in a non-invasive approach. Such biomarkers
could form the basis for specific multi-marker models for
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displaying drug-induced kidney injury in pre-clinical and clinical
application and may have substantial translational value.
Results
Identification of the rat urinary peptides indicative of cis-
platin and gentamicin induced nephrotoxicity
Two parallel approaches were employed to identify potential
biomarkers for drug-induced nephrotoxicity. The study design is
graphically depicted in figure 1. In the first approach, CE-MS
data generated in a previous study [11] were used as an initial
reference to identify biomarkers for cis-platin-induced nephrotox-
icity (table S1 sheet 1). The comparison of the urinary peptides
and proteins from 14 controls and 25 treated animals resulted in
identification of 493 peptides that showed statistically significant
changes in distribution (P,0.05 after correction for multiple
testing).
In the second approach, rat urine samples from a gentamicin
study [12] were used as a second source for nephrotoxicity
biomarker discovery. Samples were analyzed using CE-MS and
the data were matched against a previously established rat urinary
proteome database [10,11]. The compiled proteomic profiles of all
samples in this study are shown according to dose and treatment
duration in figure S1. Urine samples collected at days 3, 7 or 10
(the first samples taken after treatment) from rats treated once
daily for three consecutive days with 150 mg/kg or 300 mg/kg
gentamicin (n = 23) or saline (from all time points n = 40) were
analyzed as cases and controls, respectively, to form the discovery
set (table S1 sheet 2). A total of 557 potential biomarker
candidates could be defined (P,0.05). Of this peptide pool, 88
peptides intersected with the 493 peptides profiled in the cis-platin
study (figure 1).
Next, proteomic data from untreated animals and animals
treated with 150 or 300 mg/kg gentamicin were evaluated and a
mean amplitude was calculated for each peptide at each time point
(1,2,3,7,10,15,18,22,29,36 and 44 days) for both doses. The
distributions of all peptides (493+557) were visually inspected on a
graph with amplitude on the y-axis and treatment-time on the x-
axis for controls (0 mg), 150 and 300 mg/kg gentamicin to
determine regulation over time. This analysis revealed that 39 of
the 493 biomarker candidates responsive to cis-platin also
displayed a clear response to gentamicin (figures S2). Of the
557 potential candidate peptides from the gentamicin study, an
additional 108 peptides showed a clear gentamicin response over
the whole observation period (see figures S2). Combining the
markers of both analyses provided a list of 147 marker candidates.
Some of these peptides showed opposite regulation in the two
studies. Only peptides with a change in the same direction were
selected as drug induced nephrotoxicity markers (table S2). The
mean signal intensities of the resultant 101 potential biomarkers
are shown in figure 2.
To obtain sequence information for the nephrotoxicity marker
candidates, tandem mass spectrometry was applied. We were able
to identify 54 of the 101 marker candidates. Table 1 gives
sequence information for the 54 biomarker candidates. The
majority of the identified biomarkers were fragments of collagen
alpha-1 (I), (III) and alpha-2 (I). Fragments of apolipoprotein A-IV,
fibrinogen beta, fetuin-A, actin, hemoglobin subunit beta, inter
alpha-trypsin inhibitor, osteopontin, pro-epidermal growth factor,
prothrombin, tropomyosin-1 alpha and contrapsin-like protease
inhibitors 3 and 6 were also identified.
Evaluation of the distribution of protein fragments of
previously defined biomarkers
The U.S. FDA and European Medicines Agency (EMEA) have
qualified beta-2-microglobulin, cystatin C, clusterin, kim-1, trefoil
factor-3, albumin, total protein, and rpa-1 as biomarkers of acute
drug-induced kidney injury in the rat [13]. Recently, researchers
there described the association of clusterin, kim-1, albumin, rpa-1,
osteopontin, lipocalin-2 (NGAL), alpha GST and mu GST to
gentamicin treatment [12,14]. Our rat urinary proteome database
which contains naturally occurring peptides (defined by exact
mass, migration time, and, if available, exact sequence), but
generally not whole proteins (as these are generally not observed in
urine), was searched for peptides derived from these biomarkers.
We could identify 5 fragments of clusterin, 16 fragments of
osteopontin and 11 fragments of albumin in the rat urine. To
examine if any of these fragments are altered after treatment with
gentamicin the distribution of these 32 peptides in samples of
untreated rats (n = 40) were compared to samples of rats treated
with 150 and 300 mg/kg gentamicin collected at days 3, 7 and 10
using correction for multiple testing. One clusterin, two albumin,
and five osteopontin fragments were significantly altered (P,0.05,
see table 2) and showed a direction of regulation identical to that
of the total protein.
Generation of high-dimensional biomarker models for
drug induced nephrotoxicity in the rat
As drug-induced nephrotoxicity represents a highly complex
injury, we aimed to capture this complex pathophysiology in a
multidimensional biomarker model. To this end, we selected two
different sets of biomarker candidates for modeling purposes. First,
we used all selected 101 candidate biomarkers for nephrotoxicity
as listed in table S2. Second, we used a biomarker set composed
of those 54 candidate biomarkers that were sequenced (table 1).
Linear- and support-vector-machine (SVM)-based models for
the 101 and 54 marker combinations were generated using the 39
samples from the cis-platin study as a training set. The
classification of the cis-platin (training) data using complete take-
one-out cross-validation resulted in an AUC of 1.00 with all SVM
models. Classification with the linear model based on 54 and 101
markers yielded AUC’s of 0.87 and 0.95, respectively. Subse-
quently, samples from the gentamicin study were classified with all
generated models. Classification factors for all samples from the
gentamicin study are listed in table S3 and are shown in figure 3
A for the linear models and figure 3 B for the SVM models. The
classification factors represent a composite index of signal
intensities of all biomarkers included in the model, calculated
using linear- or SVM-based algorithms. All models showed a
similar response to gentamicin treatment over time. With the
exception of the SVM model with 54 peptides, the models showed
higher scores immediately after the first drug dose for treated
animals in comparison to untreated controls. The highest scores
were observed between days 3 and 10, shortly thereafter the scores
returned to the level of controls. Classification with the biomarker
models correlated with the administered drug dose; such that
higher doses resulted in higher classification scores.
In an effort to estimate the value and validity of the urinary
peptide biomarkers, as well as the biomarker models developed
here, we examined their correlation with the pathophysiological
changes observed and with other kidney injury biomarkers. As
evident from the data presented in table 3, significant correlation
could be established for most variables.
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Discussion
Previously, urine obtained from Sprague Dawley rats before
and after administration of cis-platin was analyzed to identify
biomarkers of drug-induced nephrotoxicity. In a blinded sample
set, a set of 34 urinary peptides was validated that demonstrated
significant differences between treated and untreated animals [11].
In the present study, all data obtained previously (discovery and
validation set) were used as a discovery set to define additional cis-
platin-induced nephrotoxicity biomarker candidates. In addition, a
set of marker candidates was defined in the urine of gentamicin
treated rats. While an overlap of injury markers existed with the
two nephrotoxins, it was quite modest. Mitochondrial injury
leading to apoptotic and necrotic cell death is common to both
nephrotoxins, however, initiating events are thought to be very
different [15–17]. Furthermore, gentamicin is recognized to have
broader nephrotoxic effects impacting the collecting ducts and
glomeruli [15] while cis-platin injury is more localized to the
proximal and distal tubules especially that segment (S3) of the
proximal tubule located in the outer medulla and the cortico-
medullary junction [18]. Data from the present study further
support that substantial differences exist on a molecular level
between cis-platin- and gentamicin-induced injury and suggest
that the toxic mechanisms of these two nephrotoxins vary
considerably and/or target different structures within the nephron.
Figure 1. Study design and rationale for biomarker selection. Depicted is the size of the sample cohorts used in the biomarker definition step
and the number of selected peptides after statistical comparison of the respective treated and control groups. Numbers of peptides identified in both
cis-platin and genatmicin treated rats as markers are denominated in the intersection of the diagrams. The significant marker candidates were visually
inspected and only those candidates were selected that showed a clear response to gentamicin. In the next step the direction of regulation was
controlled for the markers identified in both studies and selected were only those demonstrating similar (up or down) regulation with both cis-platin
and gentamicin. In the last step the number of markers for which the amino acid sequence could be resolved is listed.
doi:10.1371/journal.pone.0034606.g001
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Individually, the candidate biomarkers showed a clear response
to the gentamicin treatment. Biomarker models representing a
composite index of all marker intensities based on both cis-platin
and gentamicin specific biomarkers were generated. These models
performed well in both the cis-platin and gentamicin treated
cohorts. Longitudinal data from the gentamicin cohort revealed a
dose-dependent response immediately after the first administration
of gentamicin. The highest intensity response was observed
between days 3 and 10. These results demonstrated that the
gentamicin-induced changes in urinary peptides are rapid but
return to control levels concurrent with injury resolution. No
significant differences between the control group and the
gentamicin-treated animals were observed 4 weeks after injury.
Consistent with these peptide data, all the urinary protein
biomarkers elevated in the original study and the associated
histopathology changes [12] demonstrated the same temporal
response. The correlation with the different variables was not
uniform (e.g. highest correlation with the different histopatholog-
ical datasets was not consistently observed with one specific
biomarker), but on average the highest correlation was detected
with the biomarker model based on the 101 biomarkers, again
supporting the concept that a multi-marker model is better suited
to display complex pathophysiological changes. Furthermore,
when examining the data in a hypothesis-driven approach and
limiting the dataspace to only previously described biomarkers
[12,19–24], we could detect fragments of peptides from three of
the eight specific acute kidney injury (AKI) -associated biomarkers
(albumin, osteopontin, and clusterin) from the original study.
Using the untargeted MS it was not possible to detect fragments of
all eight AKI-associated biomarkers that were previously
described. This may be because the protein biomarkers are not
represented by specific peptides (e.g. may not fragment in the same
areas consistently or may degrade to very small fragments) and
hence cannot be detected by an approach targeted at naturally
occurring peptides. In addition, we were not able to identify the
sequence of all potential peptide biomarkers in this study. This is
due to the specific challenges associated with sequencing of
naturally occurring peptides. These challenges are described in
detail elsewhere [25]. The most prominent hurdles are poor
fragmentation and/or post-translational modifications altering the
mass, and thereby interfering with sequence assignment. It should
also be noted that the sensitivity of untargeted MS is generally
below that of targeted immunological methods. Therefore, low
abundant prototypic peptides that may represent the biomarkers
may be present but below the limit of detection with the MS
technology applied in this study.
Altered regulation of human urinary peptides in AKI and
tubular injury was previously described [26,27]. All 54 identified
sequences in this study were compared with sequenced human
urinary biomarkers for AKI [26] and for Fanconi syndrome [27].
Regulation of collagen fragments in human AKI was opposite to
that seen in the rat models described here. Generally, urinary
collagen fragments were substantially reduced in human AKI
while a significant up-regulation was observed in the rat. In
addition to inherent species differences, disease etiology and
severity could account for some response differences. In the
Figure 2. Group specific polypeptide profiles for the 101 drug-induced nephrotoxicity markers in the gentamicin-treated rat
cohort. The compiled data sets of urine samples from gentamicin-treated rats at different doses and sampling days are shown. The data sets were
divided into four groups according to the days of sampling after initiation of treatment (samples collected at day 1+2; day 3+7+10; day 15+18+22 and
day 29+36+44 from left to right) and for the gentamicin dose (0, 150 and 300 mg/kg gentamicin from the top to bottom). Molecular mass of the
analyzed polypeptides (kDa) in logarithmic scale is plotted against CE migration time (min). The mean signal intensity is represented on the z-axis of
the 3D plot.
doi:10.1371/journal.pone.0034606.g002
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Table 1. Sequenced urinary biomarkers for drug induced kidney injury.
Mass [Da] CE-T [Min]
Regulation factor in
gentamicin study p-value (BH) AUC Sequence
UniProt name
(start AA- stop AA)
1197.58 36.97 12.5 2.9E204 0.793 DSYVGDEAQSK ACTS_RAT (53–63)
1685.83 41.55 4.7 2.1E202 0.688 AFSPVASVESASGEVLH FETUA_RAT (307–323)
1215.56 38.53 1234.6 1.3E203 0.688 TIDQNLEDLR APOA4_RAT (211–220)
2070.03 30.75 9.8 2.5E204 0.823 AEGSpGRDGApGAKGDRGETGP CO1A1_RAT (1009–1030)
1998.98 30.79 86.1 0.0E+00 0.998 EGSpGRDGApGAKGDRGETGP CO1A1_RAT (1010–1030)
1366.66 39.46 16.1 1.7E202 0.667 DRGETGPAGPpGApG CO1A1_RAT (1024–1038)
2047.06 36.4 9.3 6.9E204 0.798 GApGApGPVGPAGKNGDRGETGP CO1A1_RAT (1038–1060)
1990.04 35.94 5.0 2.4E205 0.872 ApGApGPVGPAGKNGDRGETGP CO1A1_RAT (1039–1060)
1805.94 34.27 13.9 0.0E+00 0.959 GApGPVGPAGKNGDRGETGP CO1A1_RAT (1041–1060)
2048.01 30.91 87.4 1.8E203 0.710 NGDDGEAGKPGRPGERGppGP CO1A1_RAT (218–238)
1876.95 31.11 109.9 6.4E204 0.793 DDGEAGKPGRPGERGPpGp CO1A1_RAT (220–238)
1646.89 27.78 10.2 1.5E202 0.724 GEAGKPGRpGERGPpGP CO1A1_RAT (222–238)
1662.89 27.84 7.3 3.8E203 0.764 GEAGKpGRpGERGPpGP CO1A1_RAT (222–238)
2040.99 36.17 100.9 0.0E+00 0.973 NSGEpGApGNKGDTGAKGEpGP CO1A1_RAT (421–442)
1737.87 41.58 5.8 3.3E202 0.700 TGSpGSpGPDGKTGPpGPAG CO1A1_RAT (530–549)
1235.62 38.24 9.2 2.0E203 0.776 pGPDGKTGPpGPAG CO1A1_RAT (536–549)
1691.86 35.21 5.1 1.0E205 0.898 DGKTGPpGPAGQDGRPGp CO1A1_RAT (539–556)
1737.9 33.68 75.2 6.9E204 0.720 GTAGEpGKAGERGVpGPpG CO1A1_RAT (576–594)
1508.78 32.47 146.3 5.9E205 0.785 GEpGKAGERGVpGPpG CO1A1_RAT (579–594)
1451.77 32.23 6.0 8.2E203 0.831 EpGKAGERGVpGPpG CO1A1_RAT (580–594)
1550.78 40.72 76.6 4.8E204 0.726 VGPAGKDGEAGAQGApGP CO1A1_RAT (596–613)
1405.72 39.05 3.4 1.8E204 0.827 GLpGPAGPpGEAGKpG CO1A1_RAT (633–648)
1860.95 42.67 4.9 3.7E204 0.777 TGPIGPpGPAGApGDKGETGP CO1A1_RAT (755–775)
1584.8 33.97 19.6 6.0E206 0.904 DGQPGAKGEpGDTGVKG CO1A1_RAT (809–825)
1469.76 32.4 6.0 3.4E203 0.766 GQPGAKGEpGDTGVKG CO1A1_RAT (810–825)
1182.6 39.65 4.0 4.0E205 0.873 DTGVKGDAGPpGP CO1A1_RAT (820–832)
1067.56 36.83 9.4 1.5E202 0.724 TGVKGDAGPpGP CO1A1_RAT (821–832)
1844.97 34.95 18.4 2.0E206 0.927 SGNAGPpGPpGPVGKEGGKGP CO1A1_RAT (878–898)
2058.09 30.81 108.6 2.4E204 0.758 SGNAGPpGPpGPVGKEGGKGPRG CO1A1_RAT (878–900)
1590.87 27.67 5.8 3.0E206 0.920 GPpGPVGKEGGKGPRGE CO1A1_RAT (885–901)
1900.95 42.53 7.0 4.5E202 0.655 ETGPAGRpGEVGPpGPpGPAG CO1A1_RAT (901–921)
1714.81 42.32 119.1 2.4E202 0.641 TGPAGRpGEVGPpGPpGPA CO1A1_RAT (902–920)
1771.91 41.88 13.0 2.9E203 0.756 TGPAGRpGEVGPpGPpGPAG CO1A1_RAT (902–921)
1388.72 39.15 2.2 1.5E205 0.866 RpGEVGPpGPpGPAG CO1A1_RAT (907–921)
1944.02 35.43 13.6 3.0E206 0.908 RpGEVGPpGPpGPAGEKGSPG CO1A1_RAT (907–927)
1308.64 39.09 4.7 1.0E202 0.707 GLpGPSGEPGKQGp CO1A1_RAT (963–976)
1314.6 48.73 36.7 4.1E202 0.624 GNpGPpGPpGPpGPG CO2A1_RAT (1135–1149)
1441.74 32.22 31.9 0.0E+00 0.946 SpGIpGPKGEDGKDG CO3A1_RAT (453–467)
1695.81 40.95 32.4 4.8E203 0.720 GMpGSpGGPGNDGKpGPpG CO3A1_RAT (536–554)
1351.66 39.57 6.1 6.0E206 0.904 ApGDKGDAGPpGPQG CO3A1_RAT (624–638)
1558.73 48.82 10.0 7.0E206 0.892 GLpGPpGNNGNpGPpGP CO3A1_RAT (878–894)
2071.06 36.16 4.9 4.0E202 0.678 VGEpGPAGSKGETGNKGEpGSAG CO1A2_RAT (351–373)
1620.84 40.7 55.9 2.5E204 0.757 GLpGSpGNVGPAGKEGPV CO1A2_RAT (457–474)
1677.84 41.02 46.6 3.3E202 0.749 GLpGSpGNVGPAGKEGPVG CO1A2_RAT (457–475)
1142.56 36.71 10.4 3.1E203 0.751 NIGFpGPKGPSG CO1A2_RAT (497–508)
1414.68 39.01 4.9 5.9E203 0.753 LYQAEAFIADFK SPA3L_RAT (156–167)
989.49 35.54 26.6 9.3E203 0.690 IDELYLPK SPA3N_RAT (306–313)
1690.86 41.54 13.0 2.2E202 0.691 EPPSLRPAPPPISGGGY FIBB_RAT (43–59)
1711.8 40.76 7.5 2.0E202 0.759 DSFGDLSSASAImGNPK HBB1_RAT (44–60)
1163.56 37.95 6.7 2.8E202 0.720 LGDGLVGSRQY O35802_RAT (651–661)
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gentamicin rodent study, experimental kidney injury due to a toxic
insult was very apparent upon histopathology examination and
was detectable with urinary protein biomarkers. However, the
classical serum biomarkers, blood urea nitrogen and serum
creatinine, were only minimally elevated and animals never
demonstrated morbidity or clinical signs of kidney injury. In the
human study, kidney injury was generally observed in conjunction
with morbidity and/or more severe alteration of classical
biomarkers.
Perhaps more significantly, the human study encompassed AKI
of largely pre-renal or glomerular etiology while the animal models
represented drug-induced, primarily kidney tubular injury. This
may explain the difference in regulation of urinary collagen
fragments. Reduction of glomerular function has been associated
with a reduction of specific collagen fragments in the urine
[28,29]. Tubular damage resulting in reduced tubular re-
absorption and consequently in an increases of the urinary protein
and peptides secretion has been investigated in proteomic
experiments [27]. A comparison of rat nephrotoxicity markers
and human markers for tubular injury (Fanconi syndrome) [27]
reveals similarities including the elevation of urinary collagen
fragments. Interestingly, two collagen fragments were observed to
have identical cleavage sites in the human and in the rat,
indicating upregulation of similar proteases. These data give rise to
the hypothesis that the observed alterations in specific urinary
peptides may be indicative of disease-associated changes in
extracellular remodeling, displayed in the urine by increase in
the specific urinary peptides reported here.
The majority of identified biomarkers present in this study were
fragments of the collagen chains alpha-1 (I), alpha-1 (III) and
alpha-2 (I). Several of the collagen fragments had a PGP-motif at
the C-terminus, suggesting these fragments may be generated by
matrix metalloproteinase (MMP) activity. Up-regulated MMPs,
especially MMP-2 and MMP-9, have been detected following
acute kidney injury, mostly in animal models of ischemia [30,31],
and up-regulation of MMP-9 was reported to protect from
apoptosis in AKI [32]. Deregulation of MMPs, up-regulation of
MMP-2 and down-regulation of MMP-9 have also been reported
in CKD [33]. In addition, MMP-9 deletion was reported to
mitigate vascular lesions (hence insult) after ischemia [34,35]. It
appears reasonable that increases in urinary collagen fragments
may evolve from increased MMP (and possibly other protease)
activity as a result of a toxic insult. Significant up-regulation of
peptides derived from the N-terminus of Fibrinogen-beta was also
recognized. Recently, a peptide of similar origin was ascribed
nephroprotective properties [36]. The nephroprotective capability
of the Fibrinogen-beta fragment described here needs to be
evaluated. For a fibrinogen alpha chain derived peptide identified
in this study as a rat nephrotoxicity marker, a peptide homologue
in humans exists which was previously described as prognostic for
AKI development [26]. This study also identified as a potential
biomarker candidate a fragment of apolipoprotein A-IV that has
been described as predictive for progression of chronic kidney
diseases [37].
In conclusion, we have identified a panel of urinary peptide
biomarkers that are significantly associated with drug-induced
Table 1. Cont.
Mass [Da] CE-T [Min]
Regulation factor in
gentamicin study p-value (BH) AUC Sequence
UniProt name
(start AA- stop AA)
1416.68 39.34 9.0 1.1E202 0.707 ISHELESSSSEVN OSTP_RAT (305–317)
1583.81 33.26 119.5 2.8E202 0.740 DGTDYKTLLSRQMG EGF_RAT (501–514)
2082.11 31.05 44.6 4.3E202 0.633 SLTDKTEKELLDSYIDGR THRB_RAT (342–359)
1486.72 39.89 13.2 2.6E202 0.684 EELDHALNDMTSI TPM1_RABIT (272–284)
Given are molecular mass (in Da), normalized migration time (in min) regulation factor (mean signal intensity of urine samples from 150 and 300 mg/kg gentamicin
treated rats collected at days 3, 7 and 10 divided by mean signal intensity of control samples), adjusted p-value (Benjamini and Hochberg), amino acid sequence
(modified amino acids: p = hydroxyproline; k = hydroxylysine; m=oxidized methionine) and short protein name of the UniProt database with the position of the firs and
last amino acid in parenthesis.
doi:10.1371/journal.pone.0034606.t001
Table 2. Significantly changed fragments of serum albumin, osteopontin and clusterin by gentamicin induced kidney injury in
rats.
Masse [Da] CE-time [Min] Sequence Protein name (start AA- stop AA) P-value (BH)
1180.63 31.49 DEDLTSRMKS Osteopontin (171–180) 0.0196
1314.68 39.17 SQESDEAIKVIP Osteopontin (180–191) 0.0002
1326.63 39.17 TVDETYVPKEF Serum abumin (516–526) 0.0154
1416.68 39.34 ISHELESSSSEVN Osteopontin (305–317) 0.0196
1465.73 31.50 EGALDDTRDSEMK Clusterin (81–93) 0.0196
1753.77 43.58 DEQYPDATDEDLTSR Osteopontin (163–177) 0.0195
2012.96 36.86 DEQYPDATDEDLTSRMK Osteopontin (163–179) 0.0154
2406.29 22.03 EAHKSEIAHRFKDLGEQHFK Serum abumin (25–44) 0.0283
Given are molecular mass (in Da), normalized migration time (in min), amino acid sequence (modified amino acids: p = hydroxyproline; k = hydroxylysine; m= oxidized
methionine), protein name with the position of the first and last amino acid in parenthesis and p-values (adjusted according to the method of Benjamini and Hochberg).
doi:10.1371/journal.pone.0034606.t002
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nephrotoxicity in two different rat models. The biomarkers
correlate with pathophysiology and likely reflect collagen degra-
dation and changes in extracellular matrix turnover associated
with increased MMP activity. These biomarkers, and especially
the high-dimensional biomarker models, appear to be valuable for
the monitoring of early nephrotoxicity in drug safety trials. To
further establish their value and validity, we will aim at analyzing
their performance in additional studies, and also investigate their
distribution in rat models for kidney disease like the ZDF model.
Methods
All animal procedures were performed in accordance with the
U. S. Public Health Service Guide for the Care and Use of
Laboratory Animals through an animal use protocol (WO-2006-
52) approved by the White Oak Animal Program Institutional
Animal Care and Use Committee in an AAALAC-accredited
facility on the White Oak Campus of the U. S. FDA, Silver Spring,
MD.
Specimen characteristics
Urine samples from rats in a previously described cis-platin
study [11] were analyzed. Rats were given a single i.p. injection of
cis-platin (3 or 6 mg/kg). Urine samples were collected at 0, 24, 48
and 72 hrs after dosing. Details on this sample cohort are given in
table S1 sheet 1. In addition, urine samples were obtained from
rats following gentamicin administration [12]. Saline treated
controls were included with animals receiving intramuscular
injection of 150 or 300 mg/kg gentamicin once a day for up to
3 consecutive days. Urine samples were collected 24 hours
following a single dose (day 1), two consecutive daily doses (day
2), or three consecutive daily doses (day 3). Subsequently, urine
samples were collected following a recovery time (no additional
treatments) at 7,10,15,18,22,29,36 or 44 days following the first of
the three consecutive daily gentamicin doses. For each dose group,
3–4 samples were analyzed at each time point. Three control
animals from which no samples were obtained were tested as
sentinels. One control and one treated animal were removed from
the study due to non-treatment related complications. Table S1
sheet 2 includes all samples, doses and collection days for the
gentamicin study.
CE-MS analysis
150 ml urine were mixed with 150 ml of 2 M urea, 100 mM
NaCl, 10 mM NH4OH containing 0.02% SDS. Samples were
ultrafiltered using a Centristat 20 kDa cut-off centrifugal filter
(Satorius, Go¨ttingen, Germany) to eliminate high molecular
weight compounds. The filtrate was desalted using a NAP-5 gel
filtration column (GE Healthcare Bio Sciences, Uppsala, Sweden)
to remove urea and electrolytes. The sample was lyophilized in a
Christ Speed-Vac RVC 2-18/Alpha 1-2 (Christ, Germany) and
Figure 3. Time course of nephrotoxicity classification by the urinary models composed of gentamicin-sensitive polypeptide
markers. Mean classification factors obtained with the linear (left row) and SVM (right row) model variants of the marker panels AKI_rat_lin_101
(upper panel) and AKI_rat_lin_54seq (lower panel) for urine samples from untreated animals (green curve) and animals treated with 150 (blue curve)
and 300 mg/kg (red curve) gentamicin once daily for three consecutive days over time.
doi:10.1371/journal.pone.0034606.g003
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Table 3. Correlation of urinary peptide biomarkers, as well as the biomarker models with histopathology changes and other
investigated kidney injury biomarkers.
histopathology
score necrosis score apoptosis score
regeneration
score BUN
serum
creatinine albumin
UniProt name
(start AA- stop AA) rho p-value rho p-value rho p-value rho p-value rho p-value rho p-value rho p-value
CO1A1_RAT (1009–1030) 0.358 4.1E205 0.416 1.4E206 0.384 9.9E206 0.199 2.6E202 0.147 1.0E201 0.340 1.0E204 0.210 1.9E202
FETUA_RAT (307–323) 0.195 2.9E202 0.239 7.2E203 0.250 4.9E203 0.229 1.0E202 0.070 4.4E201 0.135 1.3E201 0.250 4.9E203
CO1A1_RAT (1039–1060) 0.398 4.4E206 0.430 5.5E207 0.377 1.5E205 0.220 1.4E202 20.009 9.2E201 0.346 7.8E205 0.395 5.3E206
CO3A1_RAT (624–638) 0.418 1.2E206 0.468 3.9E208 0.445 1.9E207 0.296 7.9E204 0.092 3.1E201 0.310 4.3E204 0.347 7.5E205
CO1A1_RAT (220–238) 0.306 5.2E204 0.309 4.6E204 0.284 1.4E203 0.192 3.2E202 0.081 3.7E201 0.362 3.3E205 0.374 1.8E205
CO1A1_RAT (539–556) 0.396 4.8E206 0.432 4.8E207 0.391 6.7E206 0.182 4.2E202 0.164 6.7E202 0.306 5.1E204 0.289 1.1E203
CO1A1_RAT (809–825) 0.424 8.4E207 0.461 6.3E208 0.431 5.2E207 0.301 6.4E204 0.114 2.1E201 0.307 4.9E204 0.269 2.4E203
EGF_RAT (501–514) 0.379 1.3E205 0.425 7.6E207 0.406 2.6E206 0.272 2.1E203 0.146 1.0E201 0.328 1.9E204 0.223 1.2E202
CO1A1_RAT (1024–1038) 0.249 5.1E203 0.254 4.2E203 0.240 6.9E203 0.247 5.5E203 0.081 3.7E201 0.284 1.3E203 0.203 2.3E202
HBB1_RAT (44–60) 0.188 3.6E202 0.208 2.0E202 0.161 7.3E202 0.078 3.9E201 0.126 1.6E201 0.171 5.6E202 0.174 5.2E202
ACTS_RAT (53–63) 0.391 6.3E206 0.415 1.5E206 0.350 6.3E205 0.278 1.7E203 20.040 6.6E201 0.153 8.9E202 0.207 2.1E202
CO1A1_RAT (820–832) 0.362 3.3E205 0.391 6.6E206 0.341 1.0E204 0.089 3.3E201 0.118 1.9E201 0.395 5.3E206 0.383 1.1E205
TPM1_RABIT (272–284) 0.293 9.0E204 0.239 7.3E203 0.290 1.0E203 0.205 2.2E202 0.193 3.1E202 0.063 4.9E201 0.176 5.0E202
CO1A1_RAT (1010–1030) 0.563 8.6E212 0.618 1.6E214 0.633 2.4E215 0.509 1.4E209 0.149 9.7E202 0.378 1.4E205 0.255 4.0E203
CO1A1_RAT (580–594) 0.416 1.4E206 0.446 1.8E207 0.463 5.3E208 0.271 2.2E203 0.143 1.1E201 0.198 2.7E202 0.208 2.0E202
FIBB_RAT (43–59) 0.282 1.5E203 0.335 1.3E204 0.263 3.1E203 0.149 9.6E202 0.331 1.7E204 0.241 6.8E203 0.183 4.2E202
CO1A1_RAT (901–921) 0.244 6.1E203 0.260 3.4E203 0.230 9.9E203 0.144 1.1E201 20.002 9.9E201 0.288 1.1E203 0.288 1.1E203
CO1A1_RAT (1038–1060) 0.316 3.4E204 0.319 2.8E204 0.313 3.8E204 0.151 9.2E202 0.052 5.6E201 0.283 1.4E203 0.176 5.0E202
CO1A1_RAT (1041–1060) 0.532 1.8E210 0.533 1.6E210 0.529 2.3E210 0.297 7.8E204 0.126 1.6E201 0.376 1.5E205 0.381 1.2E205
CO1A1_RAT (222–238) 0.250 4.9E203 0.270 2.3E203 0.285 1.3E203 0.109 2.3E201 0.102 2.6E201 0.341 1.0E204 0.280 1.6E203
CO1A1_RAT (222–238) 0.272 2.2E203 0.315 3.5E204 0.298 7.5E204 0.094 3.0E201 0.178 4.7E202 0.407 2.5E206 0.309 4.6E204
CO1A1_RAT (579–594) 0.399 4.1E206 0.419 1.2E206 0.408 2.3E206 0.232 9.3E203 0.382 1.1E205 0.214 1.6E202 0.246 5.7E203
CO1A1_RAT (633–648) 0.278 1.7E203 0.384 1.0E205 0.346 7.6E205 0.063 4.9E201 0.008 9.3E201 0.449 1.6E207 0.462 5.9E208
CO3A1_RAT (878–894) 0.357 4.4E205 0.488 8.0E209 0.479 1.6E208 0.355 4.9E205 0.261 3.2E203 0.246 5.7E203 0.148 9.9E202
CO1A1_RAT (963–976) 0.235 8.3E203 0.237 7.8E203 0.205 2.2E202 0.305 5.5E204 0.032 7.2E201 0.266 2.7E203 0.207 2.1E202
CO1A2_RAT (457–474) 0.317 3.2E204 0.318 3.0E204 0.330 1.7E204 0.365 2.9E205 0.079 3.8E201 0.202 2.4E202 0.236 7.9E203
CO1A2_RAT (457–475) 0.310 4.3E204 0.374 1.7E205 0.362 3.3E205 0.280 1.5E203 0.055 5.4E201 0.316 3.2E204 0.238 7.5E203
CO3A1_RAT (536–554) 0.265 2.9E203 0.224 1.2E202 0.313 3.9E204 0.218 1.5E202 20.060 5.0E201 0.163 6.9E202 0.204 2.3E202
CO2A1_RAT (1135–1149) 0.179 4.6E202 0.195 2.9E202 0.152 9.0E202 0.180 4.5E202 0.178 4.7E202 0.229 1.0E202 0.185 3.9E202
CO1A1_RAT (885–901) 0.390 6.9E206 0.455 9.5E208 0.423 9.2E207 0.146 1.0E201 0.202 2.4E202 0.439 3.0E207 0.374 1.7E205
CO1A1_RAT (810–825) 0.325 2.2E204 0.381 1.2E205 0.437 3.4E207 0.135 1.3E201 0.292 9.7E204 0.254 4.3E203 0.199 2.6E202
CO1A1_RAT (576–594) 0.370 2.1E205 0.389 7.3E206 0.336 1.3E204 0.198 2.7E202 0.235 8.4E203 0.316 3.2E204 0.305 5.4E204
SPA3N_RAT (306–313) 0.310 4.4E204 0.352 5.7E205 0.291 9.8E204 0.182 4.2E202 0.135 1.3E201 0.333 1.5E204 0.092 3.1E201
OSTP_RAT (305–317) 0.273 2.1E203 0.300 6.9E204 0.260 3.4E203 0.017 8.5E201 0.275 1.9E203 0.381 1.2E205 0.154 8.7E202
O35802_RAT (651–661) 0.141 1.2E201 0.135 1.3E201 0.105 2.4E201 0.105 2.4E201 20.016 8.6E201 0.197 2.8E202 0.087 3.3E201
SPA3L_RAT (156–167) 0.311 4.2E204 0.260 3.4E203 0.274 2.0E203 0.179 4.5E202 0.205 2.2E202 0.114 2.0E201 0.281 1.5E203
CO1A1_RAT (218–238) 0.335 1.4E204 0.373 1.8E205 0.339 1.1E204 0.363 3.1E205 0.169 5.9E202 0.269 2.4E203 0.295 8.6E204
CO1A2_RAT (497–508) 0.306 5.1E204 0.281 1.5E203 0.334 1.4E204 0.244 6.1E203 0.178 4.7E202 0.264 3.0E203 0.229 1.0E202
CO1A1_RAT (421–442) 0.565 6.8E212 0.573 3.0E212 0.501 2.6E209 0.326 2.1E204 0.184 4.0E202 0.450 1.4E207 0.302 6.2E204
CO1A1_RAT (536–549) 0.271 2.2E203 0.292 9.6E204 0.307 5.0E204 0.253 4.4E203 0.131 1.5E201 0.184 4.0E202 0.119 1.9E201
CO1A1_RAT (907–921) 0.423 8.9E207 0.415 1.5E206 0.353 5.4E205 0.249 5.1E203 0.179 4.6E202 0.223 1.2E202 0.283 1.4E203
CO1A1_RAT (907–927) 0.462 5.9E208 0.438 3.3E207 0.377 1.4E205 0.246 5.6E203 0.045 6.2E201 0.347 7.3E205 0.312 3.9E204
CO1A1_RAT (878–898) 0.408 2.3E206 0.432 4.9E207 0.404 2.9E206 0.253 4.4E203 0.182 4.2E202 0.372 1.9E205 0.259 3.5E203
CO1A1_RAT (878–900) 0.434 4.2E207 0.463 5.4E208 0.418 1.2E206 0.246 5.7E203 0.204 2.2E202 0.480 1.5E208 0.395 5.2E206
THRB_RAT (342–359) 0.205 2.2E202 0.258 3.6E203 0.220 1.4E202 0.097 2.8E201 0.212 1.8E202 0.301 6.4E204 0.178 4.7E202
CO3A1_RAT (453–467) 0.479 1.6E208 0.496 4.0E209 0.471 3.0E208 0.256 3.9E203 0.142 1.1E201 0.413 1.7E206 0.450 1.4E207
CO1A1_RAT (902–920) 0.242 6.5E203 0.291 1.0E203 0.231 9.4E203 0.147 1.0E201 0.147 1.0E201 0.146 1.0E201 0.284 1.3E203
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stored at 4uC until use. Shortly before CE-MS analysis, the
samples were re-suspended in 10 mL HPLC grade H2O.
CE-MS analysis was performed using a P/ACE MDQ capillary
electrophoresis system (Beckman Coulter, Fullerton, USA) on-line
coupled to a MicrOTOF MS (Bruker Daltonic, Bremen,
Germany). The ESI-sprayer (Agilent Technologies, Palo Alto,
CA, USA) was grounded, and the ion spray interface potential was
set 24.5 kV. Data acquisition and MS acquisition methods were
automatically controlled by the CE via contact-close-relays.
Spectra were accumulated every 3 s, over a range of m/z 350 to
3000. The analytical characteristics of the CE-MS system were
extensively investigated by Theodorescu et al. [38] and Kolch
et al. [39].
Data processing
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses using
MosaiquesVisu software [40]. We defined ‘‘rat urinary house-
keeping polypeptides’’ and calibrated the CE-MS data utilizing
545 migration time data points, 108 mass data points by applying
local and global linear regression, respectively. References of 37
highly abundant peptides were used as ‘‘internal standard
peptides’’ for ion signal intensity (amplitude) calibration using
global linear regression. The procedure to use ‘‘internal standard’’
for amplitude normalization, was shown to be a reliable method to
address both analytical and dilution variances [41]. The resulting
peak list characterizes each polypeptide by its molecular mass
[Da], normalized migration time [min] and signal intensity. All
detected peptides were deposited, matched, and annotated in a
Microsoft SQL database, allowing further analysis and compar-
ison of multiple samples. Polypeptides within different samples
were considered identical if the mass deviation was lower than
650 ppm for masses ,4.000 Da, for masses between 4.000 and
6.000 Da gradually increasing to 6150 ppm, and 150 ppm for
features .6 kDa. Acceptable migration time deviation was
,61 minutes for 19 min, gradually increasing to ,62.5 min at
50 min.
Statistical analysis
The reported P-values were calculated using the natural
logarithm transformed intensities and the Wilcoxon test. Only
peptides that were found at frequencies .30% in either case or
control group were examined. The false discovery rate (FDR)
adjustments of Banjamini-Hochberg [42] were employed to
correct for multiple testing. Receiver operator characteristic
(ROC) curves have been constructed and the area under the
ROC curve (AUC) has been calculated using MedCalc version
8.1.1.0 (MedCalc Software, Belgium, www.medcalc.be).
Sequencing
Urine samples were analysed on a Dionex Ultimate 3000 RSLS
nano flow system (Dionex, Camberly UK). After loading (5 ml)
onto a Dionex 0.1620 mm 5 mm C18 nano trap column at a
flowrate of 5 ml/min in 0.1% formic acid and 2% acetonitrile,
sample was eluted onto an Acclaim PepMap C18 nano column
75 mm615 cm, 2 mm 100 A˚ at a flow rate of 0.3 ml/min. The trap
and nano flow column were maintained at 35uC. The samples
were eluted with a gradient of solvent A: 0.1% formic acid verses
solvent B: 80% acetonitrile starting at 5% B rising to 50% B over
100 min.
The eluant was ionized using a Proxeon nano spray ESI source
(Thermo Fisher Hemel UK) operating in positive ion mode into an
Orbitrap Velos FTMS. Ionization voltage was 2.5 kV and the
capillary temperature was 200uC. The mass spectrometer was
operated in MS/MS mode scanning from 380 to 2000 amu. The
top 10 multiply charged ions were selected from each scan for
MS/MS analysis using HCD at 35% collision energy. The
resolution of ions in MS1 was 60,000 and 7,500 for HCD MS2.
Data files were searched against the IPI rat non-redundant
database using the Open Mass Spectrometry Search Algorithm
(OMSSA, http://pubchem.ncbi.nlm.nih.gov/omssa) and SE-
QUEST (by using Thermo Proteome Discoverer), without any
enzyme specificity. No fixed modification and oxidation of
methionine and proline as variable modifications were selected.
Mass error window of 10 ppm and 0.05 Da were allowed for MS
Table 3. Cont.
histopathology
score necrosis score apoptosis score
regeneration
score BUN
serum
creatinine albumin
UniProt name
(start AA- stop AA) rho p-value rho p-value rho p-value rho p-value rho p-value rho p-value rho p-value
CO1A1_RAT (902–921) 0.294 8.9E204 0.288 1.1E203 0.283 1.4E203 0.193 3.1E202 0.125 1.7E201 0.304 5.6E204 0.392 6.0E206
CO1A1_RAT (755–775) 0.310 4.4E204 0.388 7.8E206 0.357 4.4E205 0.247 5.4E203 0.123 1.7E201 0.447 1.7E207 0.302 6.2E204
CO1A1_RAT (530–549) 0.140 1.2E201 0.201 2.5E202 0.169 5.9E202 20.019 8.3E201 20.050 5.8E201 0.327 2.0E204 0.299 6.9E204
CO1A1_RAT (821–832) 0.287 1.2E203 0.342 9.4E205 0.293 9.3E204 0.091 3.1E201 0.078 3.9E201 0.246 5.6E203 0.288 1.1E203
APOA4_RAT (211–220) 0.333 1.5E204 0.381 1.1E205 0.370 2.1E205 0.317 3.2E204 0.141 1.2E201 0.206 2.1E202 0.220 1.4E202
CO1A2_RAT (351–373) 0.281 1.5E203 0.341 9.8E205 0.327 2.0E204 0.127 1.6E201 0.350 6.3E205 0.159 7.6E202 0.135 1.3E201
CO1A1_RAT (596–613) 0.354 5.0E205 0.423 9.0E207 0.377 1.5E205 0.342 9.6E205 0.050 5.8E201 0.411 2.0E206 0.296 8.2E204
Model
AKI_rat_lin_101 0.531 1.8E210 0.577 1.8E212 0.567 5.6E212 0.229 1.0E202 0.320 2.7E204 0.489 7.2E209 0.409 2.1E206
AKI_rat_lin_54seq 0.488 7.8E209 0.528 2.6E210 0.532 1.8E210 0.250 4.9E203 0.241 6.8E203 0.398 4.2E206 0.379 1.3E205
AKI_rat_SVM_101 0.568 5.0E212 0.570 3.8E212 0.492 5.6E209 0.261 3.2E203 0.406 2.7E206 0.360 3.7E205 0.385 9.0E206
AKI_rat_SVM_54seq 0.314 3.6E204 0.373 1.9E205 0.366 2.7E205 0.241 6.8E203 0.254 4.2E203 0.135 1.3E201 0.111 2.2E201
Given are short protein name of the UniProt database with the position of the firs and last amino acid in parenthesis, for the sequenced biomarkers and names of the
biomarker models, rank correlation coefficients (and p-values) between histopathology, necrosis, apoptosis, regeneration scores, classical clinical chemistry endpoints
(BUN, serum creatinine, albumin) and the detection level of the sequenced candidate biomarkers and the biomarker models\ classification scores.
doi:10.1371/journal.pone.0034606.t003
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and MS/MS, respectively. Peptide data were extracted using high
peptide confidence and top one peptide rank filters. The OMSSA
results were further optimized using COMPASS [43], 1% FDR
was used as a cut-off value. The correlation between peptide
charge at the working pH of 2 and CE-migration time was utilized
to minimize false-positive identification rates [44]: Calculated CE-
migration time based on the number of basic amino acids was
compared to the experimental migration time. Accepted were only
those peptides which were found with both search algorithms
(OMSSA and SEQUEST) and having a mass deviation below
650 ppm and a CE-migration time deviation below 62 min.
Establishment of biomarker-based classifiers
For generation of disease-specific polypeptide patterns two
different algorithms were used: Support vector machine (SVM)-
based MosaCluster software [45] and a linear combination of log-
transformed, normalized data, as described [46,47]. MosaCluster
(version 1.7.0) was developed for discrimination between different
patient groups in the high-dimensional parameter space by using
SVM learning. It generates high dimensional models, which rely
on features (biomarkers) displaying statistically significant differ-
ences between data from patients with a specific disease to controls
or other diseases. Each feature allegorizes one dimension in the n-
dimensional parameter space [48–51].
For linear combination, normalized signal intensity values
below 1 were substituted with a value of 1 to avoid negative values
by log-transformation. The average signal intensity for a specific
biomarker over all cases was compared to the average intensity for
the biomarker over all controls. To avoid artificial weighting of
specific biomarkers in the set due to the difference in observed
signal intensities for case and control, the relative distance between
the two averages (case and control) was set to a value of 2. This
relative distance of signal intensities between the disease and
control samples was provided using the formula:
Aik{meanaverages
  2
xcase{xcontrolj j ,
Aik is the log-transformed signal intensity of the i
th biomarker in
the kth sample in either set, meanaverages is the average of the mean
intensity of all possible markers for test set samples, Xcase
represents the mean observed signal intensity of the possible
biomarker from all Xcontrol cases samples and represents the mean
signal intensity of the possible biomarker from the combined
control samples.
Supporting Information
Figure S1 Capillary electrophoresis coupled to mass
spectrometry profiling of rat urine. The compiled data sets
of urine samples from gentamicin-treated rats at different doses
and sampling days are shown. Molecular mass of the analyzed
polypeptides (kDa) in logarithmic scale is plotted against CE
migration time (min). The mean signal intensity is represented in
arbitrary units on the z-axis of the 3D plot.
(PDF)
Figure S2 Time course of mean signal intensities of all
defined (n=147) nephrotoxicity peptide maker candi-
dates. Mean signal intensities of the respective peptide in urine
samples from untreated animals and animals treated once daily for
three consecutive days with 150 and 300 mg/kg gentamicin over
time are shown. The first 39 diagrams depict the selected cis-platin
markers and the subsequent figures the additional 108 gentamicin
markers.
(PDF)
Table S1 Characteristics of sample cohorts. (A) cis-
Platin cohort. The animal ID, evaluation ID, the cis-platin
dosage, time of treatment (* urine sample collected before
treatment) and the group (usage as), are given. (B) gentamicin
cohort. The animal ID, evaluation ID, the gentamicin dosage,
time of treatment and group usage, are given.
(XLS)
Table S2 Characteristics of the 101 cis-platin- and/or
gentamicin-specific polypeptides. Shown are the peptide
identification number in the dataset (Peptid ID), molecular mass
(in Da) and normalized migration time (in min). Given are the p-
values (adjusted according to Benjamini-Hochberg), AUC-values
and the regulation factor for the case group compared to the
control group for gentamicin and for cis-platin. In addition, amino
acid sequence (modified amino acids: p = hydroxyproline; k = hy-
droxylysine; m = oxidized methionine), parent protein name with
the position of the first (start) and last (stop) amino acid, and Swiss-
Prot entry numbers are given.
(XLS)
Table S3 Classification scores of gentamicin-treated
rats as determined by different biomarker models.
(XLS)
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